journal article·2024-05Open access

In Situ Formation of Fibronectin‐Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy

Zhangyi Luo, Zhuoya Wan, Pengfei Ren, Bei Zhang, Yixian Huang, Raymond E. West, Haozhe Huang, Yuang Chen, Thomas D. Nolin, Wen Xie, Junmei Wang, Song Li, Jingjing Sun

Advanced Science· Volume 11· Issue 19

Abstract

Abstract PARP inhibitors (PARPi)‐based synthetic lethal therapy demonstrates limited efficacy for most cancer types that are homologous recombination (HR) proficient. To potentiate the PARPi application, a nanocarrier based on 5‐azacytidine (AZA)‐conjugated polymer (PAZA) for the codelivery of AZA and a PARP inhibitor, BMN673 (BMN) is developed. AZA conjugation significantly decreased the nanoparticle (NP) size and increased BMN loading. Molecular dynamics simulation and experimental validations shed mechanistic insights into the self‐assembly of effective NPs. The small PAZA NPs demonstrated higher efficiency of tumor targeting and penetration than larger NPs, which is mediated by a new mechanism of active targeting that involves the recruitment of fibronectin from serum proteins following systemic administration of PAZA NPs. Furthermore, it is found that PAZA carrier sensitize the HR‐proficient nonsmall cell lung cancer (NSCLC) to BMN, a combination therapy that is more effective at a lower AZA/BMN dosage. To investigate the underlying mechanism, the tumor immune microenvironment and various gene expressions by RNAseq are explored. Moreover, the BMN/PAZA combination increased the immunogenicity and synergized with PD‐1 antibody in improving the overall therapeutic effect in an orthotopic model of lung cancer (LLC).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: PARP inhibition in cancer therapy · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Pharmacogenetics Department of Pharmaceutical Science University of Pittsburgh School of Pharmacy Pittsburgh PA 15213 USA

Department of Pharmacy and Therapeutics University of Pittsburgh School of Pharmacy Pittsburgh PA 15213 USA

Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center University of Pittsburgh School of Pharmacy Pittsburgh PA 15213 USA

Department of Pharmaceutical Sciences College of Pharmacy University of Nebraska Medical Center Omaha NE 68106 USA

Fred & Pamela Buffett Cancer Center University of Nebraska Medical Center Omaha NE 68106 USA

Funding

National Institutes of Health

References (64)

Show source-provided references
1. 10.1038/nrm.2017.5310.1038/nrm.2017.53 ↗
2. a)P.Caiafa inSpringer 2006;
3. 10.1158/1078-0432.CCR-13-139110.1158/1078-0432.CCR-13-1391 ↗
4. 10.1186/s40364-017-0081-z10.1186/s40364-017-0081-z ↗
5. 10.4161/cc.10.8.1527310.4161/cc.10.8.15273 ↗
6. 10.1158/1535-7163.MCT-15-037410.1158/1535-7163.MCT-15-0374 ↗
7. 10.1016/j.ccell.2019.12.01510.1016/j.ccell.2019.12.015 ↗
8. 10.1016/j.ccell.2016.09.00210.1016/j.ccell.2016.09.002 ↗
9. 10.1016/j.trecan.2021.12.00310.1016/j.trecan.2021.12.003 ↗
10. 10.1200/PO.20.0006910.1200/PO.20.00069 ↗
11. 10.3389/fmolb.2020.0020510.3389/fmolb.2020.00205 ↗
12. 10.1038/s41467-017-02088-w10.1038/s41467-017-02088-w ↗
13. 10.1158/0008-5472.CAN-07-025110.1158/0008-5472.CAN-07-0251 ↗
14. 10.1007/s11095-017-2311-310.1007/s11095-017-2311-3 ↗
15. 10.7150/thno.1856310.7150/thno.18563 ↗
16. 10.1158/1535-7163.MCT-09-120210.1158/1535-7163.MCT-09-1202 ↗
17. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
18. 10.1038/nnano.2015.34210.1038/nnano.2015.342 ↗
19. 10.1039/C8NR04042G10.1039/C8NR04042G ↗
20. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
21. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
22. 10.1016/j.jconrel.2008.06.01510.1016/j.jconrel.2008.06.015 ↗
23. 10.1021/la703570m10.1021/la703570m ↗
24. 10.1021/nn406388t10.1021/nn406388t ↗
25. 10.1021/acsnano.5b0021410.1021/acsnano.5b00214 ↗
26. 10.1039/c3sm27396b10.1039/c3sm27396b ↗
27. 10.1016/0006-2952(73)90137-810.1016/0006-2952(73)90137-8 ↗
28. 10.2217/pgs.15.13510.2217/pgs.15.135 ↗
29. 10.1002/jps.260068070510.1002/jps.2600680705 ↗
30. 10.4161/cl.2396710.4161/cl.23967 ↗
31. 10.1038/s41589-022-01093-510.1038/s41589-022-01093-5 ↗
32. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
33. 10.1021/acsnano.1c0858510.1021/acsnano.1c08585 ↗
34. 10.1038/309030a010.1038/309030a0 ↗
35. 10.1091/mbc.8.12.256310.1091/mbc.8.12.2563 ↗
36. Issa J. P. · Cancer Res. · 2009 · 15 · 3938
37. 10.1038/nmeth.333710.1038/nmeth.3337 ↗
38. 10.1158/2326-6066.CIR-19-015910.1158/2326-6066.CIR-19-0159 ↗
39. 10.1182/blood-2019-12289610.1182/blood-2019-122896 ↗
40. 10.1172/JCI12331910.1172/JCI123319 ↗
41. 10.1007/s10439-015-1276-910.1007/s10439-015-1276-9 ↗
42. 10.1021/nn301282m10.1021/nn301282m ↗
43. 10.1016/j.mattod.2022.11.00810.1016/j.mattod.2022.11.008 ↗
44. 10.1016/j.jconrel.2022.12.02810.1016/j.jconrel.2022.12.028 ↗
45. 10.1038/s41565-022-01266-210.1038/s41565-022-01266-2 ↗
46. 10.1038/s41467-023-44572-610.1038/s41467-023-44572-6 ↗
47. 10.1038/s41578-023-00552-210.1038/s41578-023-00552-2 ↗
48. 10.1021/acsnano.7b0020010.1021/acsnano.7b00200 ↗
49. 10.1016/j.biomaterials.2015.10.01910.1016/j.biomaterials.2015.10.019 ↗
50. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
51. 10.7150/thno.3828710.7150/thno.38287 ↗
52. 10.1016/j.actbio.2016.07.01410.1016/j.actbio.2016.07.014 ↗
53. 10.3389/fonc.2019.0035310.3389/fonc.2019.00353 ↗
54. 10.1093/nar/gkac38210.1093/nar/gkac382 ↗
55. 10.1016/j.jconrel.2012.05.01410.1016/j.jconrel.2012.05.014 ↗
56. 10.1021/acsnano.9b0843410.1021/acsnano.9b08434 ↗
57. 10.1002/0471141755.ph1427s6210.1002/0471141755.ph1427s62 ↗
58. 10.1016/j.actbio.2018.06.01010.1016/j.actbio.2018.06.010 ↗
59. 10.1371/journal.pone.011474910.1371/journal.pone.0114749 ↗
60. 10.1038/ncomms1344310.1038/ncomms13443 ↗
61. 10.1038/nprot.2016.09510.1038/nprot.2016.095 ↗
62. 10.1038/s41467-017-02088-w10.1038/s41467-017-02088-w ↗
63. Yuan F. · Cancer Res. · 1994 · 54 · 3352
64. 10.1038/nprot.2006.46810.1038/nprot.2006.468 ↗